![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 0114-9954
Source: Reactions Weekly, Vol.1, Iss.1398, 2012-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol RAPIDly rising in RA
Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol dominates in the UK and Finland
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 617, 2010-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol: a guide to its use in Crohn's disease
Drugs & Therapy Perspectives, Vol. 23, Iss. 11, 2007-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol: Psoriatic skin lesions: case report
Reactions Weekly, Vol. 1, Iss. 1326, 2010-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol a PRECiSE treatment for Crohn's disease
Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. :